Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Abeona Therapeutics (ABEO) Net Income towards Common Stockholders (2016 - 2025)

Abeona Therapeutics has reported Net Income towards Common Stockholders over the past 15 years, most recently at -$21.5 million for Q4 2025.

  • Quarterly results put Net Income towards Common Stockholders at -$21.5 million for Q4 2025, down 131.24% from a year ago — trailing twelve months through Dec 2025 was $75.0 million (up 188.66% YoY), and the annual figure for FY2025 was $67.1 million, up 205.25%.
  • Net Income towards Common Stockholders for Q4 2025 was -$21.5 million at Abeona Therapeutics, down from -$5.2 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for ABEO hit a ceiling of $113.7 million in Q2 2025 and a floor of -$46.7 million in Q4 2021.
  • Median Net Income towards Common Stockholders over the past 5 years was -$12.7 million (2024), compared with a mean of -$9.5 million.
  • Biggest five-year swings in Net Income towards Common Stockholders: tumbled 247.25% in 2024 and later surged 945.23% in 2025.
  • Abeona Therapeutics' Net Income towards Common Stockholders stood at -$46.7 million in 2021, then skyrocketed by 84.84% to -$7.1 million in 2022, then plummeted by 134.53% to -$16.6 million in 2023, then surged by 44.02% to -$9.3 million in 2024, then tumbled by 131.24% to -$21.5 million in 2025.
  • The last three reported values for Net Income towards Common Stockholders were -$21.5 million (Q4 2025), -$5.2 million (Q3 2025), and $113.7 million (Q2 2025) per Business Quant data.